Bank Julius Baer & Co
REGN icon

Bank Julius Baer & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Bank Julius Baer & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$449K Sell
718
-38,255
-98% -$26M ﹤0.01% 456
2026
Q1 		$30M Sell
38,973
-2,389
-6% -$1.83M 0.09% 127
2025
Q4 		$31.9M Buy
41,362
+39,977
+2,886% +$27.1M 0.09% 127
2025
Q3 		$778K Buy
1,385
+85
+7% +$48.1K ﹤0.01% 386
2025
Q2 		$681K Sell
1,300
-1,983
-60% -$1.11M ﹤0.01% 355
2025
Q1 		$2.08M Sell
3,283
-114,997
-97% -$79.1M 0.01% 284
2024
Q4 		$90.5M Buy
118,280
+10,291
+10% +$8.64M 0.28% 86
2024
Q3 		$129M Sell
107,989
-4,959
-4% -$5.52M 0.43% 57
2024
Q2 		$128M Sell
112,948
-4,933
-4% -$4.78M 0.49% 52
2024
Q1 		$113M Buy
117,881
+26,610
+29% +$25.3M 0.43% 65
2023
Q4 		$100M Buy
91,271
+7,170
+9% +$5.9M 0.42% 70
2023
Q3 		$69.2M Buy
84,101
+8,947
+12% +$7.03M 0.4% 66
2023
Q2 		$54M Sell
75,154
-6,280
-8% -$4.84M 0.32% 72
2023
Q1 		$66.9M Buy
81,434
+7,246
+10% +$5.47M 0.43% 62
2022
Q4 		$53.5M Sell
74,188
-27,470
-27% -$20.3M 0.37% 67
2022
Q3 		$70M Buy
101,658
+413
+0.4% +$260K 0.53% 47
2022
Q2 		$59.8M Buy
101,245
+99,535
+5,821% +$64.7M 0.42% 58
2022
Q1 		$1.19M Buy
1,710
+1,183
+224% +$748K 0.01% 266
2021
Q4 		$333K Sell
527
-8
-1% -$4.92K ﹤0.01% 470
2021
Q3 		$324K Sell
535
-292
-35% -$181K ﹤0.01% 492
2021
Q2 		$462K Buy
827
+77
+10% +$39K ﹤0.01% 460
2021
Q1 		$355K Sell
750
-111
-13% -$54K ﹤0.01% 495
2020
Q4 		$416K Buy
861
+148
+21% +$79.9K ﹤0.01% 483
2020
Q3 		$399K Sell
713
-965
-58% -$585K ﹤0.01% 414
2020
Q2 		$1.05M Buy
+1,678
New +$952K 0.01% 266

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank Julius Baer & Co's REGN Position: Q2 2026 in Review

Bank Julius Baer & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 98% in Q2 2026, selling an estimated $26M and leaving 718 shares worth $449K. The position accounts for ﹤0.01% of the portfolio, ranked #456.

Bank Julius Baer & Co first reported a position in REGN in Q2 2020 and has held it in 25 quarters since. The position peaked at $129M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Bank Julius Baer & Co held 718 shares of Regeneron Pharmaceuticals worth $449K as of Q2 2026.
  • Bank Julius Baer & Co sold 38,255 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $26M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Bank Julius Baer & Co's portfolio in Q2 2026, its #456 holding.
  • Bank Julius Baer & Co first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Bank Julius Baer & Co's Regeneron Pharmaceuticals position peaked at $129M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bank Julius Baer & Co's 13F filing for Q2 2026, filed 10 Aug 2026.